A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia by Burnett, A, Russell, N, Hills, R, Kell, J, Nielsen, O, Dennis, M, Cahalin, P, Pocock, C, Ali, S, Burns, S, Freeman, S, Milligan, D, Clark, R, behalf of the UK NCRI AML Study Group

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. by Baxter, E, Kulkarni, S, Vizmanos, J, Jaju, R, Martinelli, G, Testoni, N, Hughes, G, Salamanchuk, Z, Calasanz, M, Lahortiga, I, Pocock, C, Dang, R, Fidler, C, Wainscoat, J, Boultwood, J, Cross, N

Results of a phase 2 trial of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukemia (CMML) - the UK monocle study by Vyas, P, Hills, R, Knapper, S, Dennis, M, Drummond, M, Dillon, R, Pocock, C, Culligan, D, Wiseman, D, Zabkiewicz, J, Hodges, M, Cargo, C, Taylor, J, Upton, L, Wright, M, Bowen, D

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-... by Hillmen, P, Pettitt, A, Schuh, A, Milligan, D, Bowles, K, Bareford, D, Riaz, J, Follows, G, Rule, S, Wallis, J, Gribben, J, Noble, R, Pocock, C, Lisby, S, Carey, J, Gupta, I, Chang, C, McKeown, A

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. by Byrd, J, Brown, JR, O'Brien, S, Barrientos, J, Kay, N, Reddy, N, Coutre, S, Tam, C, Mulligan, S, Jaeger, U, Devereux, S, Barr, P, Furman, R, Kipps, T, Cymbalista, F, Pocock, C, Thornton, P, Caligaris-Cappio, F, Robak, T, Delgado, J, Schuster, S, Montillo, M, Schuh, A, de Vos, S, Gill, D